Evommune, Inc. (NYSE: EVMN) is a Healthcare company (Biotechnology) with a market capitalization of $290M. The Maz Rating grades it against the other companies in its sector.
Evommune, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.02, Evommune, Inc. trades at 1.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -43.5%, return on invested capital of -50.1% and a free cash flow yield of -31.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 8.23. Over the past 52 weeks the share price ranged from $4.94 to $33.20, with a beta of 0.96.
Evommune, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.